146 related articles for article (PubMed ID: 1835624)
1. Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide.
Marschner NW; Adler M; Nagel GA; Christmann D; Fenzl E; Upadhyaya B
Eur J Cancer; 1991; 27(9):1137-40. PubMed ID: 1835624
[TBL] [Abstract][Full Text] [Related]
2. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
[TBL] [Abstract][Full Text] [Related]
3. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group.
Kaasa S; Kvaløy S; Dicato MA; Ries F; Huys JV; Royer E; Carruthers L
Eur J Cancer; 1990 Mar; 26(3):311-4. PubMed ID: 2141487
[TBL] [Abstract][Full Text] [Related]
4. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.
De Mulder PH; Seynaeve C; Vermorken JB; van Liessum PA; Mols-Jevdevic S; Allman EL; Beranek P; Verweij J
Ann Intern Med; 1990 Dec; 113(11):834-40. PubMed ID: 2146911
[TBL] [Abstract][Full Text] [Related]
5. Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.
Marschner N
Eur J Cancer; 1991; 27 Suppl 1():S15-7; discussion S22. PubMed ID: 1831629
[TBL] [Abstract][Full Text] [Related]
6. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy.
Sledge GW; Einhorn L; Nagy C; House K
Cancer; 1992 Nov; 70(10):2524-8. PubMed ID: 1423181
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.
Fraschini G; Ciociola A; Esparza L; Templeton D; Holmes FA; Walters RS; Hortobagyi GN
J Clin Oncol; 1991 Jul; 9(7):1268-74. PubMed ID: 1828499
[TBL] [Abstract][Full Text] [Related]
8. [Long-term results of the anti-emetic effectiveness of the 5-HT3 antagonist ondansetron].
Marschner NW; Adler M; Jaenicke F; Albrecht U; Nagel GA
Onkologie; 1990 Aug; 13(4):313-5. PubMed ID: 2146577
[TBL] [Abstract][Full Text] [Related]
9. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
Levitt M; Warr D; Yelle L; Rayner HL; Lofters WS; Perrault DJ; Wilson KS; Latreille J; Potvin M; Warner E
N Engl J Med; 1993 Apr; 328(15):1081-4. PubMed ID: 8455665
[TBL] [Abstract][Full Text] [Related]
10. Role of ondansetron plus dexamethasone in fractionated chemotherapy.
Räth U; Upadhyaya BK; Arechavala E; Böckmann H; Dearnaley D; Droz JP; Fosså SD; Henriksson R; Aulitzky WE; Jones WG
Oncology; 1993; 50(3):168-72. PubMed ID: 8459987
[TBL] [Abstract][Full Text] [Related]
11. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
[TBL] [Abstract][Full Text] [Related]
12. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
Buser KS; Joss RA; Piquet D; Aapro MS; Cavalli F; Haefliger JM; Jungi WF; Bauer J; Obrist R; Brunner KW
Ann Oncol; 1993 Jun; 4(6):475-9. PubMed ID: 8353089
[TBL] [Abstract][Full Text] [Related]
13. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research.
Lancet; 1992 Jul; 340(8811):96-9. PubMed ID: 1352024
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.
Barrenetxea G; Schneider J; Centeno MM; Romero H; de la Rica M; Rodríguez-Escudero FJ
Cancer Chemother Pharmacol; 1996; 38(5):471-5. PubMed ID: 8765442
[TBL] [Abstract][Full Text] [Related]
15. Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study.
Gebbia V; Testa A; Cannata G; Gebbia N
Anticancer Drugs; 1996 Sep; 7(7):734-7. PubMed ID: 8949983
[TBL] [Abstract][Full Text] [Related]
16. A randomised, double-blind, parallel-group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy.
du Bois A; McKenna CJ; Andersson H; Lahousen M; Kitchener H; Pinter T; Capstick V; Wilkinson JR
Oncology; 1997; 54(1):7-14. PubMed ID: 8978585
[TBL] [Abstract][Full Text] [Related]
17. Antiemetic efficacy of prophylactic ondansetron in laparoscopic surgery: randomized, double-blind comparison with metoclopramide.
Raphael JH; Norton AC
Br J Anaesth; 1993 Dec; 71(6):845-8. PubMed ID: 8280551
[TBL] [Abstract][Full Text] [Related]
18. Ondansetron plus dexamethasone compared to the 'standard' metoclopramide combination.
Roila F
Oncology; 1993; 50(3):163-7. PubMed ID: 8459986
[TBL] [Abstract][Full Text] [Related]
19. Antiemetic prophylaxis with ondansetron and methylprednisolone vs metoclopramide and methylprednisolone in mild and moderately emetogenic chemotherapy.
Tsavaris NB; Koufos C; Katsikas M; Dimitrakopoulos A; Athanasiou E; Linardaki G
J Pain Symptom Manage; 1999 Sep; 18(3):218-22. PubMed ID: 10517044
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group.
Cubeddu LX; Pendergrass K; Ryan T; York M; Burton G; Meshad M; Galvin D; Ciociola AA
Am J Clin Oncol; 1994 Apr; 17(2):137-46. PubMed ID: 8141105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]